• Describe the pathogenesis of neoplasia

Reading File

Finding Sources

Reading File

I now have comprehensive content from both Robbins textbooks. Let me compile the full, well-structured answer.

Pathogenesis of Neoplasia

1. Definition and Core Concepts

Neoplasia ("new growth") is a disorder of cell growth triggered by acquired or inherited mutations affecting a single cell and its clonal progeny. These mutations alter the function of regulatory genes, conferring growth advantages that lead to excessive, autonomous proliferation independent of physiologic signals.

Three fundamental properties underlie all cancers:

Cancer is a genetic disease — caused by DNA mutations (somatic or germline) and epigenetic alterations (DNA methylation, histone modification) that deregulate growth, survival, and senescence.
Clonal evolution — genetic alterations in cancer cells are heritable, passed to daughter cells. Cells with growth/survival advantage outcompete neighbors (Darwinian selection), producing clonal tumors. Continued selection drives tumor progression, accumulating subclones with increasingly aggressive traits.
Hallmarks of cancer — these mutations collectively produce a set of phenotypic properties that govern the natural history of a cancer and its response to therapy.

Robbins Basic Pathology p. 214–215; Robbins Pathologic Basis of Disease p. 249–253

2. Cancer Genes

Three broad categories of genes are central to carcinogenesis:

Category	Normal Function	Alteration in Cancer	Examples
Proto-oncogenes	Promote normal cell growth/division	Gain-of-function → oncogene	RAS, MYC, ERBB2, BCR-ABL
Tumor suppressor genes	Brake cell proliferation	Loss-of-function (both alleles)	RB, TP53, APC, BRCA1/2
DNA repair genes	Maintain genomic integrity	Inactivation → genomic instability	MLH1, MSH2, BRCA1

Additionally, genes regulating tumor-immune interactions are increasingly recognized as recurrently mutated in cancer.

Driver vs. Passenger Mutations

Driver mutations directly contribute to cancer development or progression by altering cancer genes.
Passenger mutations are neutral, conferring no selective advantage. Tumors accumulate many passenger mutations alongside a small number of drivers.

3. Types of Genetic Lesions

Lesion Type	Mechanism	Example
Point mutations	Single nucleotide change	KRAS codon 12 in pancreatic cancer
Gene rearrangements / translocations	Fusion oncoproteins or dysregulated expression	BCR-ABL (t9;22) in CML; MYC overexpression in Burkitt lymphoma
Gene amplifications	Massive gene copy numbers → oncoproteins	ERBB2 in breast cancer; MYCN in neuroblastoma
Deletions	Loss of tumor suppressor alleles	RB deletion in retinoblastoma; CDKN2A in melanoma
Aneuploidy	Gains/losses of whole chromosomes	Widespread in solid tumors
MicroRNAs (miRNAs)	Non-coding RNAs modulate oncogenes/suppressors	miR-21 (suppresses tumor suppressors); miR-15a/16 deleted in CLL
Epigenetic changes	Methylation silencing, histone modification	Promoter hypermethylation of CDKN2A, MLH1

Robbins Basic Pathology p. 226–229; Robbins Pathologic Basis of Disease p. 282–286

4. Hallmarks of Cancer

Based on the Hanahan & Weinberg framework, the molecular pathogenesis of neoplasia produces the following cellular phenotypes:

4.1 Self-Sufficiency in Growth Signals (Oncogenes)

Normal cells require extracellular growth signals to proliferate. Cancer cells acquire independence by:

Growth factor overproduction (autocrine stimulation): e.g., glioblastomas secrete PDGF and its own receptor.
Mutated growth factor receptors with constitutive activity: e.g., ERBB2 (HER2) amplification in breast cancer; truncated EGFR in glioblastoma.
Downstream signal-transducing proteins — RAS mutations are the most common oncogenic aberration in human tumors (~15–20% all tumors; 90% of pancreatic cancers). Mutant RAS is trapped in the GTP-bound active state, continuously signaling through the RAF/MAPK and PI3K/AKT pathways. BRAF mutations occur in ~60% of melanomas; PI3K mutations in ~30% of breast carcinomas.
Non-receptor tyrosine kinases: BCR-ABL in CML produces constitutive tyrosine kinase activity, driving uncontrolled proliferation (the target of imatinib — a paradigm for targeted therapy).
Transcription factors: MYC overexpression (by translocation or amplification) drives expression of multiple growth-promoting genes.
Cyclins and CDKs: Cyclin D/CDK4 and CDK6 complexes are frequently upregulated, inactivating RB and forcing cells through the G1/S checkpoint.

4.2 Insensitivity to Growth-Inhibitory Signals (Tumor Suppressors)

Two archetypal tumor suppressors:

RB — "Governor of the Cell Cycle"

In its hypophosphorylated state, RB binds and sequesters E2F transcription factors, blocking S-phase entry.
Phosphorylation by CDK4/6–cyclin D and CDK2–cyclin E complexes releases E2F → cell cycle progression.
Loss of RB (or functional inactivation via CDK/cyclin overactivation, CDKN2A loss, or viral oncoproteins like HPV E7 and polyomavirus large T antigen) removes this checkpoint.
Dysregulation of at least one of the four key cell cycle regulators (p16/INK4a, cyclin D, CDK4, RB) is present in most human cancers.

TP53 — "Guardian of the Genome"

Acts as a sensor of DNA damage, oncogene activation, and hypoxia.
Activates CDKN1A (p21) → cell cycle arrest; activates DNA repair genes.
If damage is irreparable, TP53 triggers apoptosis (via BAX, PUMA) or senescence.
TP53 is mutated in ~50% of all human cancers. Germline TP53 mutations cause Li-Fraumeni syndrome.
Loss of p53 also promotes angiogenesis by reducing thrombospondin-1 expression and increasing VEGF.

Other tumor suppressors:

APC → inhibits WNT/β-catenin signaling; lost in 80% of colorectal cancers.
TGF-β pathway → growth inhibitory; receptors or SMADs mutated in diverse carcinomas.
PTEN → lipid phosphatase; negative regulator of PI3K/AKT; lost in breast, endometrial cancers.
VHL → degrades HIF-1α; loss leads to VEGF overexpression in renal cell carcinoma.

4.3 Altered Cellular Metabolism (Warburg Effect)

Even in the presence of oxygen, cancer cells preferentially use aerobic glycolysis (glucose → lactate) rather than oxidative phosphorylation. This seemingly inefficient strategy provides rapidly dividing cells with metabolic intermediates (carbon moieties) for biosynthesis of macromolecules — DNA, proteins, lipids — needed for new daughter cells. Oxidative phosphorylation produces abundant ATP but consumes all carbon as CO₂ and H₂O. The Warburg effect is exploited clinically by PET scanning using ¹⁸F-FDG.

Additionally, some tumors generate oncometabolites (e.g., 2-hydroxyglutarate from mutant IDH1/2 in gliomas and AML), which alter epigenetic regulation and block differentiation.

4.4 Evasion of Cell Death (Apoptosis Resistance)

Cancer cells evade apoptosis by:

BCL2 overexpression (anti-apoptotic): e.g., t(14;18) in follicular lymphoma places BCL2 under IgH promoter control.
Loss of TP53 → failure to activate pro-apoptotic genes (BAX, PUMA, NOXA).
Upregulation of survival signals (PI3K/AKT pathway inhibits BAD and caspase-9).
Autophagy: Can have dual roles — serving as a survival mechanism under nutrient stress, but also potentially tumor-suppressive in established tumors.

4.5 Limitless Replicative Potential (Immortality / Stem Cell Properties)

Normal cells undergo senescence after ~60–70 divisions (Hayflick limit), driven by progressive telomere shortening, which eventually triggers DNA damage responses. Cancer cells circumvent this by:

Upregulating telomerase (hTERT) — active in ~90% of human cancers — to maintain telomere length.
Acquiring cancer stem cell–like properties: asymmetric cell divisions that generate both self-renewing stem cells and more proliferative progenitors. Cancer stem cells may arise from transformed tissue stem cells (e.g., HSCs → CML) or from progenitors that acquire stemness mutations (e.g., AML).

4.6 Sustained Angiogenesis

Tumors >1–2 mm depend on neovascularization. Early tumors exist in an avascular state (quiescent), until an angiogenic switch — triggered by hypoxia and driver mutations — tips the balance toward pro-angiogenic factors:

Hypoxia stabilizes HIF-1α, driving transcription of VEGF and bFGF.
Loss of p53 reduces anti-angiogenic thrombospondin-1.
Mutant RAS and MYC upregulate VEGF production.
Proteases (from tumor cells and stroma) release bFGF from ECM and generate anti-angiogenic fragments (angiostatin, endostatin) from plasminogen and collagen, respectively.
Resulting vessels are abnormal — leaky, dilated, haphazard — facilitating metastasis.

Clinically targeted by bevacizumab (anti-VEGF antibody), though with modest survival benefit.

4.7 Invasion and Metastasis

The metastatic cascade involves sequential steps:

Local invasion of ECM: Cancer cells secrete matrix metalloproteinases (MMPs), serine proteases, and cathepsins that degrade basement membrane and interstitial matrix. Integrin interactions with ECM remodel → directional migration.
Epithelial-mesenchymal transition (EMT): Loss of E-cadherin (allowing detachment), gain of mesenchymal markers (vimentin, N-cadherin, fibronectin) increases motility and invasiveness. Regulated by SNAIL, TWIST, and ZEB transcription factors.
Intravasation: Entry into blood/lymphatic vessels.
Survival in circulation: Cancer cells survive as emboli (often clustered with platelets) and avoid anoikis.
Extravasation and colonization: Adhesion to endothelium → exit → growth in new site. Organ tropism is determined by chemokine/adhesion molecule compatibility (e.g., breast cancer → bone via CXCR4/CXCL12 axis).

Spread occurs by: direct seeding of body cavities, lymphatic spread (typical of carcinomas → sentinel nodes), and hematogenous spread (typical of sarcomas → lung, liver).

4.8 Evasion of Immune Surveillance

The immune system can recognize and destroy transformed cells via:

CD8+ CTLs recognizing tumor-associated antigens (TAAs) presented on MHC I.
NK cells targeting cells with reduced MHC I expression.
Antigen-presenting cells activating adaptive responses.

Tumors evade immune destruction through:

Downregulation of MHC I → invisible to CTLs.
Expression of immune checkpoints: PD-L1 on tumor cells binds PD-1 on T cells → T cell exhaustion/anergy. CTLA-4 expressed by Tregs competes with CD28 for B7 costimulatory ligands.
Secretion of immunosuppressive cytokines: TGF-β, IL-10, IDO.
Recruitment of Tregs and M2 macrophages into the tumor microenvironment.

This underpins checkpoint inhibitor immunotherapy (anti-PD-1, anti-CTLA-4), which has transformed oncology.

4.9 Cancer-Enabling Inflammation

Tumor-associated inflammation (often driven by the tumor itself) provides:

Growth factors (EGF, VEGF, FGF).
Survival signals (NF-κB activation).
Reactive oxygen species (ROS) that cause further mutagenesis.
Matrix proteases enabling invasion.

Chronic inflammatory disorders (H. pylori gastritis → gastric adenocarcinoma; chronic hepatitis B/C → hepatocellular carcinoma; IBD → colorectal cancer) are important risk factors. Effective treatment of H. pylori reduces gastric cancer risk.

4.10 Genomic Instability (Cancer Enabler)

Defects in DNA repair systems underlie the genomic instability that accelerates accumulation of driver mutations:

Repair Defect	Mechanism	Associated Cancer
Mismatch repair (MMR) deficiency	Microsatellite instability (MSI-H)	Hereditary non-polyposis colorectal cancer (Lynch syndrome) — MLH1, MSH2, MSH6
Nucleotide excision repair (NER) deficiency	Failure to repair bulky UV-induced adducts	Xeroderma pigmentosum → skin cancers
Homologous recombination defect	Failure to repair double-strand breaks	BRCA1/2 → breast, ovarian cancers; Fanconi anemia
ATM kinase mutations	Failure to sense/signal double-strand breaks	Ataxia-telangiectasia → lymphomas

5. Multistep Carcinogenesis and Clonal Evolution

Cancer does not arise from a single mutation but from the sequential accumulation of multiple driver mutations over years to decades. The classic model is colorectal carcinogenesis (Vogelstein's adenoma-carcinoma sequence):

Normal epithelium → APC loss (hyperplasia) → KRAS mutation (adenoma) → SMAD4/TGF-β loss → TP53 loss → invasive carcinoma → additional mutations → metastasis.

Each step confers a clonal advantage, leading to the selection of increasingly malignant subclones — tumor progression.

6. Carcinogenic Agents

Agent	Mechanism	Examples
Chemical carcinogens (direct-acting)	Directly alkylate DNA	Nitrogen mustard, nitrosamides
Chemical carcinogens (indirect/procarcinogens)	Require metabolic activation (CYP450)	Benzo[a]pyrene (tobacco smoke) → epoxide; aflatoxin B1 → TP53 codon 249 mutation
Radiation	UV → pyrimidine dimers (NER); ionizing → double-strand breaks	UV → skin cancer; ionizing → leukemia, thyroid cancer
Oncogenic viruses	DNA viruses insert into host genome, produce proteins that inactivate RB/TP53	HPV E6 (degrades p53), E7 (inactivates RB) → cervical cancer; EBV → Burkitt lymphoma, NPC; HBV/HCV → HCC
Oncogenic RNA retroviruses	Carry viral oncogenes (v-onc) or activate proto-oncogenes by insertional mutagenesis	HTLV-1 → adult T-cell leukemia
H. pylori	Chronic inflammation → MALT lymphoma, gastric adenocarcinoma	—

Summary Table: Inherited Cancer Syndromes

Syndrome	Gene	Cancer Risk
Familial retinoblastoma	RB	Retinoblastoma, osteosarcoma
Li-Fraumeni syndrome	TP53	Diverse sarcomas, carcinomas
Familial adenomatous polyposis	APC	Colorectal cancer
Lynch syndrome (HNPCC)	MLH1, MSH2, MSH6	Colorectal, endometrial
Familial breast/ovarian cancer	BRCA1, BRCA2	Breast, ovarian
Von Hippel-Lindau	VHL	Renal cell carcinoma, hemangioblastoma
Neurofibromatosis 1	NF1	Neurofibromas, malignant nerve sheath tumors
MEN 1 / MEN 2	MEN1 / RET	Parathyroid, pituitary, pancreatic / MTC, pheo
Xeroderma pigmentosum	NER genes	Skin cancers

Sources:

Robbins & Kumar Basic Pathology, 11th ed. — Chapter 6 (Neoplasia), pp. 214–229
Robbins, Cotran & Kumar Pathologic Basis of Disease, 10th ed. — Chapter 7 (Neoplasia), pp. 249–300

explain the nomenclature of cancers and major terminology associated with cancers. and Differentiate between benign and malignant tumors

Reading File

I now have all the content needed. Let me compile the comprehensive answer.

Nomenclature of Tumors and Key Terminology

Core Definitions

Term	Definition
Neoplasia	"New growth" — a disorder of cell growth triggered by mutations, causing excessive autonomous proliferation independent of physiologic controls
Neoplasm / Tumor	The mass of cells arising from neoplastic transformation. Tumor originally meant any swelling (including inflammatory) but is now synonymous with neoplasm
Oncology	Study of tumors (Greek: oncos = tumor, logos = study)
Cancer	Collective term for all malignant neoplasms; derived from Latin for "crab" — because cancers invade and seize surrounding tissues in an obstinate manner
Transformation	The process by which a normal cell acquires the properties of a neoplastic cell
Parenchyma	The neoplastic cell component — determines the tumor's biologic behavior and gives it its name
Stroma	Host-derived, non-neoplastic supporting tissue (connective tissue, blood vessels, immune cells) — essential for tumor growth
Desmoplasia	Abundant collagenous stroma induced by some cancers, producing a stony-hard ("scirrhous") consistency (e.g., breast carcinoma)

Nomenclature System

Benign Tumors

The suffix -oma is appended to the cell/tissue of origin:

Suffix / Term	Cell/Tissue of Origin	Example
-oma (general)	Mesenchymal cells	Fibroma (fibroblasts), Lipoma (fat), Chondroma (cartilage), Osteoma (bone), Leiomyoma (smooth muscle), Rhabdomyoma (skeletal muscle)
Adenoma	Glandular / epithelial tissue	Renal tubular adenoma, Adrenal cortical adenoma, Colonic tubular adenoma
Papilloma	Epithelium forming fingerlike projections	Squamous papilloma, Transitional cell papilloma
Polyp	Any tumor projecting above a mucosal surface into a lumen	Colonic adenomatous polyp (Note: some polyps are inflammatory, not neoplastic)
Cystadenoma	Glandular epithelium forming large cystic spaces	Serous / mucinous cystadenoma of ovary
Papillary cystadenoma	Papillary projections protruding into cystic spaces	Papillary cystadenoma of ovary
Hemangioma	Blood vessels	Cavernous/capillary hemangioma
Lymphangioma	Lymphatics	—
Meningioma	Meninges	—
Neurofibroma	Neural tissue	—

Malignant Tumors

Naming follows the benign pattern but indicates malignancy:

Carcinomas — malignant tumors of epithelial origin

Term	Meaning	Example
Carcinoma (general)	Malignant epithelial tumor	—
Adenocarcinoma	Carcinoma growing in glandular pattern	Colonic adenocarcinoma, Breast adenocarcinoma
Squamous cell carcinoma	Carcinoma forming squamous cells	Lung SCC, Cervical SCC, Skin SCC
Transitional cell carcinoma (urothelial carcinoma)	From transitional epithelium	Bladder carcinoma
Hepatocellular carcinoma	From hepatocytes	Liver cancer
Renal cell carcinoma	From renal tubular epithelium	Kidney cancer
Bronchogenic carcinoma	From bronchial epithelium	Lung cancer
Undifferentiated/anaplastic carcinoma	No recognizable differentiation (~2% of cancers)	—

Sarcomas — malignant tumors of mesenchymal origin

Term	Tissue of Origin	Example
Fibrosarcoma	Fibroblasts	—
Liposarcoma	Fat	—
Chondrosarcoma	Cartilage	—
Osteosarcoma	Bone	—
Leiomyosarcoma	Smooth muscle	—
Rhabdomyosarcoma	Skeletal muscle	—
Angiosarcoma	Blood vessels	—

Haematopoietic / Lymphoid Malignancies

Term	Meaning
Leukemia	Malignant proliferation of haematopoietic cells circulating in blood ("white blood")
Lymphoma	Malignant solid tumour of lymphocytes/precursors (despite "-oma" ending = malignant)

Mixed Tumors

Some tumors show divergent differentiation from a single neoplastic clone:

Mixed tumor (pleomorphic adenoma): Prototype — salivary gland tumour containing both epithelial components and myxoid stroma with cartilage/bone. Benign but locally recurrent if incompletely excised.
Teratoma: Contains mature or immature cells from more than one germ layer (sometimes all three). Arises from totipotent germ cells (ovary, testis, midline rests). May be:
- Mature (benign): e.g., dermoid cyst of ovary — contains squamous epithelium, hair follicles, teeth, sebaceous glands
- Immature (malignant): Contains primitive, embryonic-type tissues

Eponymous / Confusing Exceptions

Several malignant tumors carry benign-sounding "-oma" names — deeply entrenched in usage:

Name	Behavior	Origin
Lymphoma	Malignant	Lymphocytes
Melanoma	Malignant	Melanocytes
Mesothelioma	Malignant	Mesothelium
Seminoma	Malignant	Germ cells (testis)
Hepatoblastoma	Malignant	Liver precursor cells
Glioma	Mostly malignant	Glial cells
Hamartoma	Benign (anomalous)	Disorganized tissue resembling the site; clonal but not truly neoplastic
Choristoma	Benign (anomalous)	Heterotopic nest of normal cells in wrong location (e.g., pancreatic tissue in gastric wall) — technically not a neoplasm

Key Terminology for Tumor Biology

Term	Definition
Differentiation	Extent to which tumor cells resemble their normal cell of origin (morphologically and functionally)
Anaplasia	Lack of differentiation; "backward formation." Hallmark of malignancy
Pleomorphism	Variation in size and shape of tumor cells and their nuclei
Dysplasia	"Disordered growth" — loss of uniformity and architectural orientation in epithelial cells; a premalignant change
Carcinoma in situ (CIS)	Severe dysplasia involving full epithelial thickness but not penetrating the basement membrane; preinvasive; high risk of progression
Metaplasia	Replacement of one mature cell type by another (e.g., squamous → glandular in Barrett esophagus); an adaptive response to injury, not neoplastic in itself
Invasion	Penetration of basement membrane and surrounding tissues by tumor cells
Metastasis	Spread of tumor to physically discontinuous sites — unequivocal sign of malignancy
Desmoplasia	Dense fibrous stromal reaction induced by some carcinomas
Oncogene	Mutated/overexpressed proto-oncogene that promotes cell growth
Tumor suppressor gene	Gene whose normal function brakes cell proliferation; loss promotes cancer
Grading	Histologic assessment of degree of differentiation (Grade 1 = well differentiated → Grade 3/4 = poorly differentiated/anaplastic)
Staging	Clinical/pathological assessment of tumor extent (size, lymph node involvement, metastases) — TNM system

Differentiation: Benign vs. Malignant Tumors

The three cardinal features distinguishing benign from malignant tumors are: (1) differentiation and anaplasia, (2) local invasion, and (3) metastasis. Growth rate is also useful but less reliable.

Detailed Comparison Table

Feature	Benign	Malignant
Differentiation	Well differentiated; closely resembles cell of origin	Variable — well, moderately, or poorly differentiated (anaplastic)
Anaplasia	Absent	Present to varying degrees; marked in high-grade tumors
Pleomorphism	Minimal	Often prominent (variable cell and nuclear size/shape)
Nuclear morphology	Normal N:C ratio, fine chromatin, small nucleoli	Large, hyperchromatic nuclei; coarse chromatin; prominent nucleoli; high N:C ratio (approaches 1:1 vs. normal 1:4–6)
Mitoses	Rare; normal configuration	Numerous; atypical/bizarre mitoses (multipolar spindles, asymmetric)
Tumor giant cells	Absent	May be present (pleomorphic or multinucleated giant cells)
Growth rate	Slow	Usually rapid (exceptions exist)
Growth pattern	Expansile, cohesive, pushes adjacent tissue	Infiltrative, destructive, lacks defined borders
Capsule	Usually encapsulated — rim of compressed fibrous tissue	No capsule — irregular, infiltrative margins
Local invasion	Absent — does not penetrate basement membrane	Present — invades basement membrane, ECM, blood/lymphatic vessels
Metastasis	Never	Hallmark of malignancy — present in ~30% of solid tumors at diagnosis
Recurrence after surgery	Rare	Common (incomplete excision, microinvasion)
Effect on host	Usually benign; can cause morbidity if near vital structures	Cachexia, paraneoplastic syndromes, direct organ destruction, death
Vascularity	Normal or modestly increased	Abnormal neovascularization (leaky, disorganized tumor vessels)
Stroma	Normal	May induce desmoplasia
Prognosis	Excellent; usually curable by excision	Variable; depends on grade, stage, type

Differentiation and Anaplasia in Detail

Benign tumors show well-differentiated cells that retain the functional and morphologic characteristics of their origin:

A lipoma contains mature fat cells laden with lipid vacuoles — indistinguishable from normal adipocytes.
A chondroma contains mature cartilage cells synthesizing cartilaginous matrix.
Mitoses are rare and of normal configuration.
Well-differentiated neoplasms of endocrine glands may even elaborate the hormones of their normal counterpart (e.g., TSH-secreting pituitary adenoma).

Malignant tumors exhibit anaplasia, which in its extreme form shows:

Pleomorphism — cells varying enormously in size and shape, from small undifferentiated cells to tumor giant cells.
Abnormal nuclear morphology — large, irregular, hyperchromatic nuclei with coarsely clumped chromatin at the nuclear membrane; N:C ratio approaches 1:1.
Atypical mitoses — tripolar, quadripolar, or other bizarre spindle configurations.
Loss of polarity — disordered architectural arrangement of cells.
Tumor giant cells — some with single enormous nuclei, others with two or more hyperchromatic nuclei (not to be confused with inflammatory Langhans giant cells).

Local Invasion

Benign tumors expand slowly and develop a fibrous capsule (ECM deposited by compressed stromal fibroblasts). This makes them discrete, moveable, and surgically enucleatable. Exceptions: hemangiomas and uterine leiomyomas may lack true capsules yet remain benign.
Malignant tumors lack capsules. They invade adjacent tissue as irregular, crab-like projections, penetrating basement membranes, ECM, and vessel walls. Even when a cancer appears grossly circumscribed, it is essential to excise a wide margin of apparently normal tissue to ensure complete removal. This invasiveness makes cure by surgery alone difficult in advanced cases.

Metastasis

Metastasis — spread to physically discontinuous sites — unequivocally marks a tumor as malignant. No benign tumor ever metastasizes.

Routes of spread:

Direct seeding of body cavities — e.g., ovarian carcinoma seeding the peritoneum.
Lymphatic spread — typical of carcinomas; follows regional lymph node drainage (e.g., breast cancer → axillary nodes; lung cancer → hilar/mediastinal nodes).
Hematogenous spread — typical of sarcomas; veins > arteries. Common sites: liver (portal drainage), lungs (systemic venous return), bone (vertebral venous plexus).

Notable exceptions that are malignant but rarely metastasize: basal cell carcinoma of skin and most primary CNS tumors (gliomas) — invasive locally but very rarely spread systemically. This shows that invasiveness and metastasis are biologically separable properties.

Leukemias and lymphomas are always considered malignant — they arise from cells that normally circulate, so dissemination at diagnosis is the rule.

Sources: Robbins & Kumar Basic Pathology, 11th ed., pp. 214–222; Robbins, Cotran & Kumar Pathologic Basis of Disease, 10th ed., pp. 249–262

explain the routes of metastasis and Describe the role of carcinogenic agents and their cellular interactions.

Reading File

Finding Sources

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.